Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 87 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Cassatt Patient Safety Organization - P0136
Component of Parent Org(s):
  • Cassatt RRG Holding Company
Effective Date and Time of Initial Listing: October 24, 2012 12:01 AM ET
PSO Mailing Address: 1200 Atwater Drive, Suite 180, MALVERN, PA 19355
PSO Phone Number: 610-296-2558
Point of Contact: Maureen P. Barnes
Point of Contact Phone: 484-321-5593
Point of Contact Email: mbarnes@cassattrrg.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 10/24/2018 through 10/23/2020
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
HPI Press Ganey PSO - P0185
Component of Parent Org(s):
  • Press Ganey
Effective Date and Time of Initial Listing: December 12, 2016 12:01 AM ET
PSO Mailing Address: 5041 Corporate Woods Drive Ste 180, Virginia Beach, VA 23462
PSO Phone Number: 913-800-4954
Point of Contact: Caryn Lea Woods
Point of Contact Phone: (757) 226-7479
Point of Contact Email: Caryn.Woods@pressganey.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/12/2018 through 12/11/2020
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No